AKTS (Aktis Oncology) Total Liabilities: $70.69 Mil (As of Mar. 2026)


AKTS Aktis Oncology Inc AKTS
9 GF Score
Price $31.76
! 3 Warning Signs
View Full Analysis

What is Aktis Oncology Total Liabilities?

Aktis Oncology AKTS +2.82% 9 Total Liabilities is $70.69 Mil as of Mar. 2026. GuruFocus rates AKTS with a GF Score™ of 9/100. The stock has 3 warning signs investors should review.

Aktis Oncology's Total Liabilities for the quarter that ended in Mar. 2026 was $70.69 Mil.

Aktis Oncology's quarterly Total Liabilities declined from Sep. 2025 ($411.43 Mil) to Dec. 2025 ($411.03 Mil) and declined from Dec. 2025 ($411.03 Mil) to Mar. 2026 ($70.69 Mil).

Aktis Oncology's annual Total Liabilities increased from Dec. 2023 ($168.66 Mil) to Dec. 2024 ($413.98 Mil) but then declined from Dec. 2024 ($413.98 Mil) to Dec. 2025 ($411.03 Mil).

Aktis Oncology Total Liabilities Historical Data

* Premium members only.

The historical data trend for Aktis Oncology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aktis Oncology Total Liabilities Chart

Aktis Oncology Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Liabilities
157.55 168.66 413.98 411.03

Aktis Oncology Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial 413.98 0.00 411.43 411.03 70.69
AKTS
9GF Score
Aktis Oncology Inc AKTS
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aktis Oncology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Aktis Oncology's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=31.236+(10.233+333.409
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+36.156+0+0)
=411.03

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=264.885--146.149
=411.03

Aktis Oncology's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=27.913+(10.147+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+32.633+0+0)
=70.69

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=576.801-506.108
=70.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $70.69 Mil mean?
Aktis Oncology (AKTS) has a Total Liabilities of $70.69 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Aktis Oncology and its competitors.
Is Aktis Oncology's Total Liabilities too high?
Aktis Oncology's current Total Liabilities is $70.69 Mil. Overall, Aktis Oncology has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Aktis Oncology's Total Liabilities compare to ZBIO and MLTX?
Aktis Oncology's Total Liabilities of $70.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Aktis Oncology and its competitors. Aktis Oncology's current Total Liabilities is $70.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aktis Oncology stock overvalued right now?
Aktis Oncology (AKTS) has a current Total Liabilities of $70.69 Mil. The current Total Liabilities is $70.69 Mil. Aktis Oncology's overall GF Score™ is 9/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Aktis Oncology (AKTS), the current Total Liabilities is $70.69 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aktis Oncology Business Description

Address 17 Drydock Avenue, Suite 17-401, Boston, MA, USA, 02210
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
9GF Score

Get the complete analysis for AKTS

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.76
Price